Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Appoints Steven Ruben Vice President, Protein Therapeutics

Rockville, MD - April 17, 2003

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that Steven M. Ruben, Ph.D., has been appointed Vice President, Protein Therapeutics, effective April 21, 2003. Dr. Ruben will report to Robert Booth, Ph.D., Chief Scientific Officer, Celera Genomics.

In this new position, Dr. Ruben will lead programs to discover and validate novel targets for therapeutic antibody intervention. He will oversee the established cell biology, protein chemistry, and mass spectrometry efforts ongoing at Celera's Rockville campus.

"Steve brings to Celera a proven track record of moving programs forward from target discovery through therapeutic candidate selection," said Dr. Booth. "Steve's experience with protein therapeutics and project leadership, and his successful history of interaction with collaborative partners, is relevant to the advancement of our proteomics program."

Dr. Ruben has over 15 years of experience leading research in molecular biology and protein chemistry. He brings to Celera extensive experience in target identification and validation, preclinical and clinical development, sample acquisition and protein therapeutics. In his most recent position, Dr. Ruben was Vice President, Research for Human Genome Sciences, where he was employed for the past 10 years. In this role, he led a team that was responsible for identification of therapeutic candidates and targets through DNA sequencing, expression profiling, bioinformatics and high throughput screening efforts. He participated in the creation of Human Genome Sciences' antibody program and was integrally involved in several therapeutic collaborations. Under his leadership, numerous compounds advanced through advanced preclinical evaluations, including two protein therapeutic candidates that are currently in human clinical studies.

Dr. Ruben has authored many scientific papers, and he is identified as a co-inventor on over fifty issued US patents.

About Celera Genomics and Applera Corporation
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets and to discover and develop new therapeutics. Its Celera Discovery SystemTM online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.